The work of organisations such as the Beckley Foundation has helped create more interest in alternative options to the current drug control paradigm than ever before. It is becoming increasingly clear that the ‘War on Drugs’ has failed, so Amanda Feilding undertook the present report to address the growing appetite for drug policy reform.
The Report will assess the harms related to four substance-types: cannabis, psychedelics, MDMA (‘Ecstasy’), and new psychoactive substances (NPS). It will formulate models of strict regulation based on the developing evidence-base, and propose methodological tools for assessing the benefits and harms of the different regulatory models, which could be adapted to different national realities.
On 26 May 2016, the New Psychoactive Substances Act passed into UK law, rendering it illegal to buy, sell or supply any substance deemed to have psychoactive properties.
But what will happen to the public appetite for “legal highs,” and what will happen to the drugs themselves?
To mark the day, Amanda Feilding and the Beckley Foundation have released this chapter on NPS from our forthcoming report, “Roadmaps to Regulation: Cannabis, Psychedelics, MDMA and NPS.” The chapter explains the medical and social fallacies of applying a blanket ban to this vast array of chemically dissimilar substances, and strategises how we could legally regulate the unquellable market for NPS.
Psilocybin for Depression
Type of publication